

Groups issue advisory about alpha-blockers, iris syndrome

Publish date: Oct 1, 2006 By: Cheryl Guttman

Email | Print | Share | Save | License

Urology Times

Linthicum, MD—AUA has partnered with two leading ophthalmology groups to raise awareness that individuals with past or present use of an alpha-1 blocker may develop a condition known as intraoperative floppy iris syndrome (IFIS) while undergoing cataract surgery and should inform their ophthalmologist about such medication use so that appropriate surgical techniques can be used.

IFIS occurs as a result of the action the alpha-1 blocker on the iris dilator muscle, and it can be associated with an increased risk of some cataract surgical complications if the operating ophthalmologist is not anticipating the condition (see, "What is IFIS?"). However, results of a prospective trial including more than 160 eyes of patients taking the alpha-blocker tamsulosin (Flomax) demonstrate cataract surgery can be completed safely and successfully if the surgeon knows a patient is taking or has taken an alpha-blocker, and so is able to employ appropriate surgical techniques.

Other currently marketed alpha-blockers are alfuzosin (Uroxatral), doxazosin ^{Dr. Ross} (Cardura), and terazosin (Hytrin).

In August, AUA, the American Society of Cataract and Refractive Surgery (ASCRS), and the American Academy of Ophthalmology (AAO) sponsored a media conference call and issued a press release to launch an educational campaign targeting physicians who prescribe alphablockers and the patients who are taking them about the importance of providing this medication history to the ophthalmologist prior to cataract surgery.

"The alpha-1 blockers are a commonly prescribed group of medications, particularly for men with BPH, but they are also used to treat other men and women with lower urinary tract symptoms." said Lawrence S. Ross, MD, AUA president. "Therefore, it is critical to recognize that the potential for IFIS is with a class of drugs and not just with their use in men with BPH.

"So that these patients are not put at increased risk of complications at the time of cataract surgery, they need to be counseled about the importance of mentioning past or current use of an alpha-1 blocker to their ophthalmologist." A similar advisory was issued by the Council for Refractive Surgery Quality Assistance about patients who are taking alpha-blockers and who may be considering undergoing refractive lens exchange, an alternative to Lasik laser eye surgery.



What is IFIS?

Studies indicate that the risk of IFIS is not eliminated by discontinuation of the alpha-blocker. In fact, IFIS has occurred in patients who had stopped taking an alpha-blocker up to 5 years earlier, so it is critical that patients be informed to indicate any past use to their ophthalmologist if they are candidates for cataract surgery.



POPULAR ARTICLES

Weight-based dosing: Extended-release minocycline efficient, predictable

search, START HERE

FDA warns Allergan on Aczone promotion

Exit Accutane: Derms' reactions mixed as Roche pulls long-standing remedy

Gaining control: Birth control pills, spironolactone first-line treatments for hormonal acne

Getting to the root: Look below the surface for cause of hyperandrogenetic symptoms

MORE POPULAR ARTICLES

	More Jo

SPONSORED MEDIA

OTLA Video Player

Multimedia: Why Patients Considering an IUC May Say YES to ParaGard

sponsored multimediaPromiseb A non steroidal topical cream for managing seborrheic dermatitis

MORE MEDIA

Given that medication cessation is not protective and because it can result in urinary complications, patients taking an alpha-blocker should also be counseled against stopping their medication on their own prior to cataract surgery.

"Stopping one of these agents abruptly can result in urinary retention, especially in men with prostatic disease, and that risk may be further increased in this situation because atropine treatment is one of the strategies used by cataract surgeons to manage IFIS," noted Dr. Ross, who is professor and head of urology at the University of Illinois, Chicago.



To inform urologists of the issues concerning alpha-blockers, AUA sent a press release to all members via e-mail, Dr. Ross said. In addition, updates to AUA practice guidelines will address these matters when appropriate.



POST A COMMENT

Email Address	Your e	email address will NOT be published.	
		ars with your comment	
Display Name	appea	appears with your comment	
City			
State			
Country			
Remember me: 🔍 Yes 🍭	No		
Comment read our privacy po		cy policy	
ATEST PRACTICE NEWS			
LATEST PRACTICE NEWS		LATEST DRUG NEWS	
Rural Residents More Likely	to Have Total Joint	LATEST DRUG NEWS Cetuximab Linked to Resection of Liver Metastases	
Rural Residents More Likely Replacement			
Rural Residents More Likely		Cetuximab Linked to Resection of Liver Metastases	
Rural Residents More Likely Replacement Jninsured Show Higher Risk	for Death Following	Cetuximab Linked to Resection of Liver Metastases H1N1 Influenza Rates Drop in Many States	

SNS: Web Surfing Linked to Brain Function in Older Adults

_ More

Customized Email Alerts

Modern Medicine

Get the information you want... When you want it.

→ More



Clinical Perspectives Business Perspectives Popular Topics CME/CE Coding Counselor Acne Adolescent Medicine Liability & Risk Management Coding Counselor Health Care Information Allergy & Immunology **eNewsletters** Technology Alzheimer's Disease Patient Education Center Practice Management Asthma Blogs **Business Operations** BPH Discussions Human Resources ModernMedicine Radio Breast Cancer Health Law & Policy

ModernMedicine Bringing together Advanstar's trusted healthcare journals along with powerful tools, resource, decision support and advisory functions



Home | About Us | ModernMedicine Team | Editorial and Advertising Policy | Our Publications | Terms & Conditions | Contact Us | Medical News | Medical Articles | CME Center | Patient Education | Practice Management | All Content | Privacy Policy | Terms of Use | Linking and RSS Policy © 2009 Advanstar Communications, Inc. All rights reserved. Reproduction in whole or in part is prohibited. Please send any technical comments or questions to our webmaster.